McLeskey S W, Tobias C A, Vezza P R, Filie A C, Kern F G, Hanfelt J
Lombardi Cancer Center, Department of Pharmacology, and School of Nursing, Georgetown University Medical Center, Washington, DC 20007, USA.
Am J Pathol. 1998 Dec;153(6):1993-2006. doi: 10.1016/S0002-9440(10)65713-6.
We have previously shown that fibroblast growth factor (FGF)-1-, FGF-4-, or vascular endothelial growth factor (VEGF/VPF)-transfected MCF-7 breast carcinoma cells growing as tumors in nude mice are tamoxifen resistant and/or estrogen independent. These transfectants provide opportunity for study of in situ tumor-induced angiogenesis promoted by the individual angiogenic factors under growth-promoting versus growth-inhibiting hormonal conditions. In the present study, vessels in tumors harvested at varying times after tumor cell injection were immunohistochemically highlighted and vessel morphology and topography were scored on a scale of 0 to 4 by blinded observers. In tumors produced by all cell lines under all growth-promoting hormonal conditions, there was significantly increased abundance (P < 0.05) of edge-associated and intratumor microvessels, but not of stromally located microvessels, when compared with tumor nodules harvested under growth-inhibiting conditions, regardless of the identity of the angiogenic factor or the hormonal treatment. Image analysis of bromodeoxyuridine (BrdU)-labeled nuclei of tumors produced by all cell lines under all hormonal conditions harvested at early time points showed that mean labeling indices were highest for hormonal conditions that produced the most robust growth in that particular cell line, implying that a high BrdU labeling index is a predictor of future tumor growth in individual tumors. These results confirm previous studies that established the importance of neovascularization for tumor growth and provide validation for use of these cell lines to study the process of angiogenesis in vivo. Study of gene expression in endothelial cells in edge-associated or intratumor vessels using this model might reveal mechanisms important in tumor-induced angiogenesis in human breast cancer.
我们之前已经表明,在裸鼠体内生长成肿瘤的成纤维细胞生长因子(FGF)-1、FGF-4或血管内皮生长因子(VEGF/VPF)转染的MCF-7乳腺癌细胞对他莫昔芬耐药和/或不依赖雌激素。这些转染细胞为研究在促进生长与抑制生长的激素条件下,由单个血管生成因子促进的原位肿瘤诱导血管生成提供了机会。在本研究中,对肿瘤细胞注射后不同时间收获的肿瘤中的血管进行免疫组织化学染色,由不知情的观察者对血管形态和拓扑结构进行0至4级评分。在所有促进生长的激素条件下,所有细胞系产生的肿瘤中,与在抑制生长条件下收获的肿瘤结节相比,边缘相关和肿瘤内微血管的丰度显著增加(P<0.05),但基质中微血管的丰度没有增加,无论血管生成因子的身份或激素处理如何。对所有细胞系在所有激素条件下早期收获的肿瘤中溴脱氧尿苷(BrdU)标记的细胞核进行图像分析表明,对于在该特定细胞系中产生最强生长的激素条件,平均标记指数最高,这意味着高BrdU标记指数是个体肿瘤未来生长的预测指标。这些结果证实了先前的研究,即新血管生成对肿瘤生长的重要性,并为使用这些细胞系研究体内血管生成过程提供了验证。使用该模型研究边缘相关或肿瘤内血管内皮细胞中的基因表达,可能揭示人类乳腺癌肿瘤诱导血管生成中重要的机制。